Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
JOYFINAC-P is a fixed-dose combination medication containing aceclofenac and paracetamol (acetaminophen), marketed by JoY Pharma for its analgesic and anti-inflammatory properties. Aceclofenac is a non-steroidal anti-inflammatory drug (NSAID) that primarily acts as a potent inhibitor of the cyclooxygenase-2 (COX-2) enzyme, thereby reducing the synthesis of inflammatory prostaglandins. Paracetamol is a widely used analgesic and antipyretic agent that provides complementary pain relief, likely through the inhibition of prostaglandin synthesis within the central nervous system. This combination is typically indicated for the symptomatic relief of pain and inflammation associated with musculoskeletal disorders such as osteoarthritis, rheumatoid arthritis, and ankylosing spondylitis.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on JOYFINAC-P.